RxDoctor Payments Data

Irina Seliverstov

Nurse Practitioner · Lynn, MANPI 1386646099

Payments from drug & device makers

$2,866in general payments, 2019–2025

Across 62 payments — averaging $46.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$360
  • Boehringer Ingelheim$292
  • Madrigal Pharmaceuticals$288
  • AstraZeneca$227
  • Eisai Inc.$202
  • AbbVie$190
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$2,866100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,866 in reported general payments places this provider in the 95th percentile of 3,855 nurse practitioner providers in Massachusetts.

See all nurse practitioner providers in Massachusetts

Medicare billing

Part B allowed, 2024
$7,942
Medicare patients
53
Services billed
103

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban15$8,651
Rosuvastatin Calcium20$748
Albuterol Sulfate HfaAlbuterol Sulfate14$457
Torsemide29$438
Metoprolol Succinate44$433
Atorvastatin Calcium42$375
Omeprazole21$329
Nitroglycerin PatchNitroglycerin12$282
Gabapentin22$229
Isosorbide Mononitrate ErIsosorbide Mononitrate12$203
Mupirocin12$184
Amlodipine Besylate28$171
Terazosin Hcl11$161
Finasteride13$160
Warfarin Sodium14$136

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$11$8,65115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,855 nurse practitioner providers in Massachusetts.

Other nurse practitioner in Lynn

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →